LB
Therapeutic Areas
Cosmo Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Methylene Blue MMX® (Lucipera) | Detection of colorectal polyps | Approved |
| Uceris® (budesonide MMX®) | Mild-to-moderate ulcerative colitis | Approved |
| Aemcolo® (rifamycin SV MMX®) | Travelers' diarrhea | Approved |
| CB-03-01 (Breezula®) | Acne vulgaris | Phase 3 |
| Gleto® (rifamycin SV MMX®) | Prevention of recurrent diverticulitis | Phase 3 |
| Rifamycin SV MMX® | Hepatic encephalopathy | Phase 2 |
| Methylene Blue MMX® | Ulcerative colitis | Preclinical |
| COSMO-232 | Inflammatory Bowel Disease (IBD) | Preclinical |
Leadership Team at Cosmo Pharmaceuticals
MA
Mauro Ajani
Founder, Chief Executive Officer (CEO) and Chairman of the Board
LG
Luca G. Lotti
Chief Financial Officer (CFO)
DH
Diana Harbort
Chief Executive Officer of Cosmo Technologies Ltd.
CN
Christer Nordstedt
Senior Vice President, Head of Research & Development
DD
Danilo Del Monte
Chief Operating Officer (COO)
GR
Gianluca Rattazzi
Board Member
CL
Clara L.C. Lotti
Board Member
LL
Lorenzo Lotti
Board Member
AD
Alessandro Della Chà
Chief Executive Officer of Cassiopea S.p.A.